Wednesday, June 10, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 28 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 9120851

    Human antibodies to human angiopoietin-like protein 4

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 1, 2015 · Expires Aug 27, 2035

    granted

  2. US 9089599

    Low affinity FCGR deficient mice

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 28, 2015 · Expires Jul 23, 2035

    granted

  3. US 9079948

    Human antibodies to Fel d1 and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 14, 2015 · Expires Jul 9, 2035

    granted

  4. US 9056130

    Humanized Fc gamma R mice

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 16, 2015 · Expires Jun 11, 2035

    granted

  5. US 9043996

    Genetically modified major histocompatibility complex animals

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 2, 2015 · Expires May 28, 2035

    granted

  6. US 9028819

    Methods of alleviating itch by administering human antibodies to human protease-activated receptor 2

    REGENERON PHARMACEUTICALS, INC. · Granted May 12, 2015 · Expires May 7, 2035

    granted

  7. US 9018356

    Anti-ANGPTL3 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 28, 2015 · Expires Apr 23, 2035

    granted

  8. US 9017670

    Anti-Tie2 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 28, 2015 · Expires Apr 23, 2035

    granted

  9. US 9005617

    Antikine antibodies that bind to multiple CC chemokines

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 14, 2015 · Expires Apr 9, 2035

    granted

  10. US 8987420

    High affinity human antibodies to human angiopoietin-2

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 24, 2015 · Expires Mar 19, 2035

    granted

  11. US 8980268

    Methods for treating cancer by administering an anti-Ang-2 antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 17, 2015 · Expires Mar 12, 2035

    granted

  12. US 8968736

    Human antibodies to GFRα3 and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 3, 2015 · Expires Feb 26, 2035

    granted

  13. US 8945559

    Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 3, 2015 · Expires Jan 29, 2035

    granted

  14. US 8927233

    Fusion polypeptides capable of activating receptors

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 6, 2015 · Expires Jan 1, 2035

    granted

  15. US 8921316

    Stable liquid VEGF antagonist formulations

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 30, 2014 · Expires Dec 25, 2034

    granted

  16. US 8889133

    Methods of treating diabetes with Dll4 antagonists

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 18, 2014 · Expires Nov 13, 2034

    granted

  17. US 8871209

    Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 28, 2014 · Expires Oct 23, 2034

    granted

  18. US 8865430

    Fusion polypeptides capable of activating receptors

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 21, 2014 · Expires Oct 16, 2034

    granted

  19. US 8847004

    Humanized M-CSF mice

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 30, 2014 · Expires Sep 25, 2034

    granted

  20. US 8840886

    Method of treating cancer with DLL4 antagonist and chemotherapeutic agent

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted

  21. US 8840894

    Antibodies to human GDF8

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted

  22. US 8802107

    VEGF antagonist formulations for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 12, 2014 · Expires Aug 7, 2034

    granted

  23. US 8795669

    Stabilized formulations containing anti-PCSK9 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted

  24. US 8791244

    Anti-ErbB3 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 29, 2014 · Expires Jul 24, 2034

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.